Head of the Laboratory of the Subsidiary of the Holding – Research Institute for Biological Safety Problems, PhD in Biological Sciences

A specialist in epizootiology, veterinary virology, cell biotechnology, and immunology. Author of more than 80 scientific publications, including 20 innovative patents and one monograph. Member of the Expert Council of the Institute and the editorial board of the journal Biosafety and Biotechnology.

In recognition of her contributions to the development and production of the QazVac vaccine against COVID-19, she was awarded the “Halyk Algysy” (People’s Gratitude) medal in 2021.

Key Achievements:

Under the task “Development of an inactivated vaccine against coronavirus infection COVID-19” within the framework of the Targeted Scientific and Technical Program “Development of a Vaccine against Coronavirus Infection COVID-19”, the following were obtained:

• Patent of the Republic of Kazakhstan No. 34762 dated 08.12.2020 for the strain “SARS-CoV-2/KZ_Almaty/04.2020” of the coronavirus infection COVID-19, used for the preparation of specific prophylactic agents, laboratory diagnostics, and evaluation of the biological protection effectiveness of the COVID-19 vaccine;
• Patent of the Republic of Kazakhstan No. 34761 dated 08.12.2020 for the method of obtaining an inactivated vaccine for the prevention of COVID-19.

Under the task “Development of a live vaccine based on an attenuated SARS-CoV-2 virus” within the same program, the following patents were obtained:

• Patent No. 35175 for the attenuated strain “SARS-CoV-2/RIIBSP-2021” of the coronavirus infection COVID-19, used for the development of specific prophylactic agents and laboratory diagnostics;
• Patent of the Republic of Kazakhstan No. 35526 for the strain “SARS-CoV-2/Indian-Delta/KZ_Almaty/07.2021”, a genetic variant of the “Indian-Delta” strain of SARS-CoV-2, used for vaccine development and for evaluating the effectiveness of biological protection provided by vaccines;
• Patent of the Republic of Kazakhstan No. 35528 for the strain “SARS-CoV-2/Britain/KZ_Almaty/05.2021”, a genetic variant of the “British” strain of SARS-CoV-2, used for vaccine development and evaluation of vaccine-induced biological protection.